# US 2026/0098847 A1 · Textured film for use in a dissolution adapter and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098847 A1
- Document ID: US20260098847A1
- Status: Published application
- Kind: A1
- Application number: 19/350,768
- Filed: 2025-10-06
- Published: 2026-04-09
- Earliest claimed: 2024-10-04
- Assignees: University of Connecticut
- Applicants: University of Connecticut
- Inventors: Diane J. BURGESS; Xiaoyi WANG
- Web page: https://patentgrep.com/patent/US20260098847A1

## CPC

- G01N 33/15: Medicinal preparations {; Physical properties thereof, e.g. dissolubility}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein is a film for receiving an implant formulation for in vitro testing, the film comprising a roughened surface and a scribed area on the roughened surface for receiving an in situ forming implant formulation; the in situ formulation comprising a pharmaceutically acceptable therapeutic molecule, a biodegradable polymer, a water-miscible solvent, or any combination thereof; and where a surface roughness of the roughened surface is operative to control a surface to volume ratio of the in situ forming implant formulation when tested in a dissolution adapter and/or a cassette such that a Level A in vitro-in vivo correlation is obtained.

## Claims

### Claim 1

A film for receiving an implant formulation for in vitro testing, the film comprising:
a roughened surface;
a scribed area on the roughened surface for receiving an in situ forming implant formulation; the in situ formulation comprising a pharmaceutically acceptable therapeutic molecule, a biodegradable polymer, a water-miscible solvent, or any combination thereof; and
where a surface roughness of the roughened surface is operative to control a surface to volume ratio of the in situ forming implant formulation when tested in a dissolution adapter and/or a cassette such that a Level A in vitro-in vivo correlation is obtained.

### Claim 2 (depends on 1)

The film of claim 1, wherein the film comprises a sandblasted glass slide, a porcelain slide, or a polymeric slide.

### Claim 3 (depends on 1)

The film of claim 1, wherein the scribed area comprises an open receptacle, the open receptacle having a diameter of about 0.5 cm to about 8 cm.

### Claim 4 (depends on 3)

The film of claim 3, wherein the open receptacle is selected from the group consisting of a created ring with a plane surface, a cylindrical well, or a round-bottom concave.

### Claim 5 (depends on 1)

The film of claim 1, wherein the surface roughness has an average value Ra of about 0.1 to about 5 micrometers.

### Claim 6 (depends on 3)

The film of claim 3, wherein the receptacle confines the in situ implant formulation to a defined geometry to control the surface-to-volume ratio exposed to the dissolution medium.

### Claim 7 (depends on 1)

The film of claim 1, wherein the film comprises a ceramic, a polymer, or a combination thereof.

### Claim 8 (depends on 7)

The film of claim 7, where the ceramic comprises a metal oxide, a metal carbide, a metal nitride, a metal boride, a metal silicide, a metal oxycarbide, a metal oxynitride, a metal boronitride, a metal carbonitride, a metal borocarbide, or a combination thereof.

### Claim 9 (depends on 8)

The film of claim 8, where the metal oxide comprises silicon dioxide in the form of a glass slide.

### Claim 10 (depends on 7)

The film of claim 7, where the polymer comprises a polyacrylic, a polycarbonate, a polyalkyd, a polystyrene, a polyolefin, a polyester, a polyamide, a polyaramid, a polyamideimide, a polyarylate, a polyurethane, an epoxy, a phenolic, a polysiloxane, a polyarylsulfone, a polyethersulfone, a polyphenylene sulfide, a polysulfone, a polyimide, a polyetherimide, a polytetrafluoroethylene, a polyetherketone, a polyether ether ketone, a polyether ketone ketone, a polybenzoxazole, a polyoxadiazole, a polybenzothiazole, a polybenzothiazinophenothiazine, a polypyrazinoquinoxaline, a polypyromellitimide, a polyguinoxaline, a polybenzimidazole, a polyoxindole, a polyoxoisoindoline, a polydioxoisoindoline, a polytriazine, a polypyridazine, a polypiperazine, a polypyridine, a polypiperidine, a polytriazole, a polypyrazole, a polycarborane, a polyoxabicyclononane, a polydibenzofuran, a polyphthalide, a polyacetal, a polyanhydride, a polyvinyl ether, a polyvinyl thioether, a polyvinyl alcohol, a polyvinyl ketone, a polyvinyl halide, a polyvinyl nitrile, a polyvinyl ester, a polysulfonate, a polysulfide, a polythioester, a polysulfone, a polysulfonamide, a polyurea, a polyphosphazene, a polysilazane, a polyolefin, or a combination thereof.

### Claim 11 (depends on 7)

The film of claim 7, where the polymer comprises a polyolefin, a polytetrafluoroethylene, a polysiloxane, a polyester, or a combination thereof.

### Claim 12 (depends on 1)

The film of claim 1, where the roughened surface is produced by abrasive blasting using sand, fine grit alumina, glass beads, or is produced by pore-forming technology, chemical etching, plasma etching, ion beam etching, or a combination thereof.

### Claim 13 (depends on 1)

The film of claim 1, where the roughened surface controls a surface-to-volume ratio of the in situ forming implant formulation in a solidified form that is effective to closely mimic in vivo conditions.

### Claim 14 (depends on 1)

The film of claim 1, where the roughened surface has a random texture or a periodic texture.

### Claim 15 (depends on 1)

An article that contains the film of claim 1, where the article is a dissolution adapter or a cassette.

### Claim 16

A method of establishing an in vitro-in vivo correlation (IVIVC) for a pharmaceutically acceptable therapeutic molecule, the method comprising:
disposing an in situ formulation comprising the pharmaceutically acceptable therapeutic molecule, a biodegradable polymer and a solvent into a roughened surface of a film, the roughened surface comprising a scribed receptacle that is operative to confine the formulation to a defined geometry;
disposing the film into a dissolution adapter where it is subjected to a dissolution solvent;
subjecting the dissolution adapter to in vitro release testing in a dissolution vessel selected from USP Apparatus 1, USP apparatus 2, USP Apparatus 4, or a screw-capped bottle in a water bath shaker, and collecting medium samples over time to determine the in vitro release profile;
administering the formulation to a subject and collecting plasma samples over time to determine an in vivo pharmacokinetic profile;
processing the in vivo pharmacokinetic profile by deconvolution to determine an in vivo absorption profile; and
correlating the in vitro release profile with the in vivo absorption profile to establish a Level A IVIVC.

### Claim 17 (depends on 16)

The method of claim 16, wherein the dissolution medium comprises a buffered aqueous solution selected from phosphate-buffered saline, simulated body fluid, Hank's balanced salt solution, Tris buffer, acetate buffer, or carbonate buffer.

### Claim 18 (depends on 16)

The method of claim 16, wherein the film comprises a sandblasted glass slide, a porcelain slide, or a polymeric slide.

### Claim 19 (depends on 16)

The method of claim 16, where the roughened surface is produced by abrasive blasting using sand, fine grit alumina, glass beads, or is produced by pore-forming technology, chemical etching, plasma etching, ion beam etching, or a combination thereof.

### Claim 20 (depends on 16)

The method of claim 16, where the roughened surface controls a surface-to-volume ratio of the in situ forming implant formulation in a solidified form that is effective to closely mimic in vivo conditions.
